NIH's Healy: Although Her Impact Has Been Powerful, Questions Remain About Her Long-Term Influence

Praise for some of her achievements is tempered by ongoing concern over future NIH strategies What will be the long-term impact of Bernadine Healy's brief two years as the first woman director of the National Institutes of Health? With her recently announced resignation, effective June 30, the fate of projects and issues she has pressed for or influenced becomes less clear. Among these are her creation of a women's health office at the institutes, her development of a strategic plan for NIH re

Written byFranklin Hoke
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

What will be the long-term impact of Bernadine Healy's brief two years as the first woman director of the National Institutes of Health? With her recently announced resignation, effective June 30, the fate of projects and issues she has pressed for or influenced becomes less clear. Among these are her creation of a women's health office at the institutes, her development of a strategic plan for NIH research, and her impact on scientific integrity investigations in the biomedical community.

According to scientists, former NIH officials, and policy advocates, Healy's lasting influence will be significant-- impressively so, in light of the relatively short duration of her tenure--although it may not be exactly what she might have hoped for in every case.

The ability of David Kessler, the 41-year-old commissioner of the Food and Drug Administration, to survive the purge of Bush appointees by the Clinton administration is an achievement being greeted ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies